We may soon have a third major COVID-19 vaccine on the way, as Novavax (NVAX) seeks to join Pfizer and Moderna for approval and widespread distribution. Novavax announced today that its experimental vaccine would enter phase three study in the U.S. Its vaccine is already in phase three in the U.K. The U.S. federal government
With countless polls across the country from a variety of sources, including this one from the Associated Press, reporting that roughly half of all Americans are still very much on the fence about getting the COVID-19 vaccine, the U.S. Government continues to march forward. Today, it was announced that Pfizer (PFE) and its drugmaking partner BioNTech
Take your pick… there’s more than enough reasons to call this year historic. While most are worth forgetting, looking back on the urgency and efficiency at which drugmakers around the world developed and distributed an approved COVID-19 is impressive. With all hands on deck, a process that usually takes up to 5-10 years was accomplished
Since the pandemic reared its ugly head earlier this year, the names Pfizer (PFE), BioNTech (BNTX), Moderna (MRNA), AstraZeneca (AZN) and more all became household names and the fixture of portfolios everywhere. While it’s fair that since these names headlined much of the news around Operation Warp Speed, leading the nation’s race to develop an
With the novel coronavirus stealing the show this year, innovation in the biotech space has been just… a little overshadowed by the race to develop a worldwide vaccine. Considering the pandemic has taken more than 1.6 million lives across the globe, the “all-hands-on-deck” approach is certainly understandable. But just because the vaccine race has taken
There has been much more than enough news around the race to develop an effective COVID-19 vaccine this year to make your head spin. We’ve all seen the names. Pfizer (PFE), BioNTech (BNTX), Moderna (MRNA), AstraZeneca (AZN), Johnson & Johnson (JNJ) and a host of others… they’ve all been claiming trial results showing 90%, 94%,
The race to produce a bonafide, FDA-approved COVID-19 vaccine has been a tightly contested race between drugmakers across the world who all want to be the first to market. The competition has been great, as it’s led to an approved vaccine in a matter of 10 months, rather than the usual 5-10 years it would
Let’s take a minute to appreciate at least one bit of positive news that’s come out of 2020. It may seem like it’s been an eternity, but the fact that seen a COVID-19 developed and approved in the timeframe of 2020 is a modern marvel of science. Normally, a vaccine like this would take years
Two weeks ago, after Pfizer (PFE) released revised results of its late-stage vaccine trials, showing efficacy had increased from 90% to 95% among the company’s test subjects, it filed for the first U.S. emergency use authorization. In the race to be the first drugmaker to distribute an approved COVID-19 vaccine, Pfizer, in collaboration with BioNTech
Back when Pfizer (PFE) and BioNTech (BNTX), released their late-stage trial vaccine results, showing 90% efficacy, the world let out a deep sigh of relief. But there’s a bit of a hangup, the vaccine must be shipped and stored at Arctic-like temperatures of minus 70 degrees Celsius. The company, in conjunction with its research partner
On the vaccine front, obviously, major drugmakers like Pfizer (PFE), BioNTech (BNTX), Moderna (MRNA) and AstraZeneca (AZN) have dominated headlines over the last few weeks. Elsewhere, Eli Lilly (LLY) and Gilead Sciences (GILD) have been making noise of their own after receiving emergency use authorization from the FDA for their therapeutics, which may be just
The virus that was developed at “warp speed” is almost at the point of distribution. U.S. officials plan to send out 6.4 million doses in the first round across the nation. They gave states and other jurisdictions an estimate of their allotments so they can make plans on how to further distribute the drug. Last
After months of headlines defined by rising hospitalizations and deaths, business closures, state-wide lockdowns and an economic recession, it’s been nice to see more positives headlines, reveling a light at the end of the tunnel. In the last couple of weeks, we’ve seen a flood of announcements from Pfizer (PFE) and BioNTech (BNTX), and Modera
